Collectively, our data suggest that PRMT3-mediated methylation of HSP60 at R446 prevents the activation of anti-tumor immunity through the maintenance of mitochondrial integrity and inhibition of cGAS/ STING activation HCC in vitro and in vivo. The gene discussed is PRMT3; the disease is hepatocellular carcinoma.